Melbourne-based wearable sensing and robotics company DorsaVi Limited (ASX: DVL) has secured an exclusive worldwide licence to two robotics intellectual property assets developed at Nanyang Technological University Singapore (NTU Singapore), expanding its technology stack into collaborative robotics, rehabilitation exoskeletons and autonomous industrial systems.
The 10-year licence agreement covers two separate inventions - a safety-aware collaborative robot control system that is the subject of a US patent application, and a proprietary know-how package for resistive random-access memory (RRAM) based neuromorphic computing architectures designed for robot learning.
Total consideration for the licence is about $320,000 exclusive of patent cost recovery obligations, with no royalty payments on product sales. As part of the transaction, DorsaVi will also issue five million fully paid ordinary shares to financial advisory Clayton Capital.
NTU Singapore ranks among Asia's leading engineering and technology universities, and the licensed IP is designed to give robots the ability to detect and respond to human presence in shared workspaces while enabling more energy-efficient on-device learning.
DorsaVi says the RRAM-neuromorphic architecture delivers projected performance improvements of 10 times over conventional computing approaches, based on technical modelling and evaluation rather than demonstrated hardware results.
The company describes the licence as completing what it calls a "vertically integrated robotics intelligence stack", combining its existing wearable motion-sensing technology with compute, memory, safety control and robot learning capabilities.
DorsaVi has been progressively pivoting from its origins in biomechanical wearable sensors toward broader robotics and neuromorphic computing applications.
Group CEO Mat Regan says the agreement is the deliberate conclusion of a sequenced acquisition strategy rather than an opportunistic deal.
“The license completes an important part of a strategy we have been building step by step," says Regan.
"We identified exoskeletons and human-robot collaboration as priority application markets.
"We validated that our RRAM and neuromorphic technologies can operate together as a coherent architecture, with modelling and technical evaluation indicating the potential for approximately 10x performance improvements in targeted robotics and exoskeleton applications.
"We launched the developer platform to enable partner engagement and commenced the hardware build program to translate the technology into a manufacturable product.
"With the NTU IP license, we now add the safety control and robot learning capabilities that complement the sensing, compute and memory technologies already under development."
Regan says DorsaVi's commercialisation pathway encompasses licensing to original equipment manufacturers, data-as-a-service models and integrated partnerships.
"The strategic logic is clear. DorsaVi’s sensors already generate clinically validated human movement data in realworld environments," he says.
"Invention 1 provides a safety control framework designed for human-robot interaction. Invention 2 provides a methodology for acquiring and organising movement data that may support robot training and adaptation.
"Together, these capabilities expand the potential application of dorsaVi’s technology into collaborative robotics, rehabilitation systems and human-machine interfaces."
Regan says these are "foundational capabilities" for the exoskeleton and cobot markets.
"We have validated key elements of our semiconductor architecture, launched the developer platform, commenced the hardware program and now secured robotics-focused intellectual property that complements those initiatives.
"Collectively, these programs establish the foundations of a differentiated robotics intelligence platform spanning sensing, memory, compute, safety and learning.
"We have been building this deliberately and sequentially, and this license represents another important step in that strategy.”
The two licensed inventions sit at different stages of IP protection. The collaborative robot safety control system is covered by a US patent application, while the RRAM-neuromorphic robot learning technology is classified as "know-how" and does not yet have patent protection.
DorsaVi is targeting several large and fast-growing global markets.
The collaborative robotics sector is projected to exceed US$17 billion ($26.5 billion) by 2030, while the robotics AI software and data market is forecast to surpass US$78 billion ($121.5 billion) by 2032.
The global exoskeleton market, another target application for the licensed technology, is estimated at US$590 million ($919 million) in 2025 and projected to reach US$2 billion ($3.1 billion) by 2033.
Shares in DorsaVi surged 38 per cent to a high of 4.1c in early trading this morning, before retreating to 3.85c by 12.12pm (AEST).
Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support